Pra Health
NASDAQ:PRAH (6/30/2021, 7:12:54 PM)
After market: 166.01 +0.8 (+0.48%)165.21
-2.8 (-1.67%)
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.
Pra Health
4130 Parklake Ave Ste 400
Raleigh NORTH CAROLINA 27612
P: 19197868200.0
CEO: Colin Shannon
Employees: 18100.0
Website: http://www.prahs.com
Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component PRA Health Sciences Inc (PRAH) was identified as having a larger market cap than the smaller end of the S&P 500, for example F5 Networks, Inc. (FFIV), according to The Online Investor..
Here you can normally see the latest stock twits on PRAH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: